Navigation Links
A Novel Oral Anticoagulant is Planned to be Developed for Patients with Prosthetic Heart Valves or Chronic Renal Dysfunction
Date:3/8/2013

ation therapy is difficult to manage well, even if closely monitored, particularly if they take medicines or foods that affect these enzymes.  Recent data shows that these drug metabolizing enzymes are down regulated in patients with chronic renal dysfunction or failure which may explain the sub-optimal anti-coagulation control with warfarin or with the novel non-monitored OACs in these patients.

Monitoring the effectiveness of warfarin in many cases requires patients to travel frequently to a local clinic to have their anticoagulation status checked and, if needed, doses adjusted.  Recently, perhaps due to reimbursement by healthcare providers, there has been an increase in patient self-monitoring and management of anticoagulation therapy that is currently only applicable to VKOR inhibitors such as tecarfarin. Ultimately, this system could provide many patients with a cost-effective management of anticoagulation therapy with a better patient compliance than with new oral non-monitored OACs.

About Tecarfarin

Tecarfarin (ATI-5923) is potentially a best-in-class orally active vitamin K epoxide (VKOR) inhibitor that was specifically designed to avoid CYP2C9 dependent metabolism and to avoid transport by P-gp. This may mean tecarfarin will need less monitoring than warfarin, potentially resulting in better patient compliance if used together with widely available self-monitoring systems. Unlike the novel non-monitored OACs, tecarfarin has an antidote, vitamin K that is readily available and can be used to rapidly reverse the anticoagulation effect of tecarfarin in an emergency. If approved, tecarfarin could become a superior anticoagulation management solution to warfarin.

About Armetheon

Armetheon, Inc. is a privately held San Francisco Bay area based clinical stage biopharmaceutical company focused on the development of novel drugs for highly unmet need. The company has 3 programs in mid - to late - clinical stage developm
'/>"/>

SOURCE Armetheon, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
3. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
4. Scripps Doctors Study Novel New Device to Diagnose Irregular Heart Beat
5. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. New Data Support Role of Prometheus Laboratories Novel Assay in Optimizing IBD Treatment Management
8. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
9. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
10. OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers
11. CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  EP Global Communications, Inc. (Public ... recently contacted the Company about discussing EPGL,s electronic ... as Monday, August 3, 2015.  Novartis CEO ... that the coming electronic contact lens market could ... the next several years.  Novartis partnered with Google ...
(Date:7/30/2015)... PLAINFIELD, N.J., July 30, 2015 PTC Therapeutics, ... update and reported financial results for the second quarter ... progressing on many fronts across the organization.  We are ... Duchenne muscular dystrophy clinical trial ever conducted with topline ... Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Translarna ...
(Date:7/30/2015)... 2015  Growth of the U.S. nonprescription market is ... prescription users to the OTC market. Due to an ... Rx-to-OTC switch activity over the next five years with ... new brands entering the market into existing categories. ... years (even those with low to moderate likelihood), the ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... builds on company,s suite of tests to evaluate ... a leading clinical-diagnostics and biomedical-research laboratory specializing in ... diagnostic assay designed to help physicians better understand ... The company will introduce the Pneumococcal Antibody ...
... March 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") ... it has started patient enrolment in a Phase ... in combination with paclitaxel and carboplatin in patients ... or EGFR-activated tumours. The Principal Investigator is Dr. ...
Cached Medicine Technology:IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting, Booth 729 2Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 2
(Date:7/31/2015)... , ... July 31, 2015 , ... In the most ... U.S. District Court in the Northern District of Illinois, Androgel testosterone attorneys report that ... 20, a docket entry was made recording the minutes of the status conference, which ...
(Date:7/31/2015)... ... July 31, 2015 , ... Intellitec Solutions announced today ... of Microsoft Dynamics GP for a senior living facility in Maine. Having achieved ... living communities in 16 states. This further expansion was again a factor of ...
(Date:7/30/2015)... ... ... When responsible for the care of an aging loved one, summer vacations ... What happens if mom falls? Who will remind Dad to take his medications? What ... not taking time away from caregiving responsibilities can lead to bigger problems – caregiver ...
(Date:7/30/2015)... ... 2015 , ... On July 22nd the Bradenton Herald reported the ... for controlling the heroin outbreak. Ultimately the committee expressed lack of funding, and the ... heroin crisis in North Florida. The task force has proposed to instate counselors to ...
(Date:7/30/2015)... ... July 30, 2015 , ... The ... BioPharma, Inc. are pleased to announce that data standards for clinical research in ... on the CDISC website . These three Therapeutic Area (TA) standards were ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5
... planned spinoff later this summer , , SAN DIEGO, ... public following the planned spinoff of Cardinal Health,s clinical and ... the occasion by providing opportunities for its global employees to ... "This is an exciting day for our company and employees ...
... (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime, Chief ... on Thursday, July 30, at 5:00 p.m. ET (23:00 CET) to ... U.S. / Canada Dial-in Number: 866.272.9941, ... 45596036, Replay Dial-in Number: 888.286.8010, ...
... Women are more vulnerable during certain stages of ... News) -- Fluctuating hormone levels may explain trends ... diseases such as Parkinson,s, schizophrenia, Alzheimer,s, Tourette,s and ... level changes occur at various stages of women,s ...
... amoxicillin in kids, , WEDNESDAY, July 1 (HealthDay News) ... infections in young children increases the risk of recurrent ... the Netherlands who called for more prudent use of ... 63 percent of children given the antibiotic amoxicillin experienced ...
... safety in those who think the same way, research contends ... you believe, new research suggests that you,re likely to surround ... be friends or talking heads on television. , "Never having ... way of protecting your beliefs. It,s a little bit primitive, ...
... WOODLANDS, Texas, July 1 eCardio Diagnostics ... arrhythmia monitoring services, today announced that it has received a ... round of institutional funding since the company was founded in ... marks a milestone in the growth of eCardio," noted Larry ...
Cached Medicine News:Health News:CareFusion Launches New Brand, Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety 2Health News:CareFusion Launches New Brand, Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety 3Health News:BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday, July 30 at 5:00 p.m. ET (23:00 CET) 2Health News:Hormones May Affect Neurological Disease Risk 2Health News:Antibiotics May Boost Risk for Recurrent Ear Infection 2Health News:Your Surroundings Mirror Your Beliefs 2Health News:Your Surroundings Mirror Your Beliefs 3Health News:eCardio Receives Significant Investment in Private Funding from Sequoia Capital 2
... Microalbumin Strips provide albumin, creatinine and albumin-to-creatinine ... Microalbumin product is useful to test for ... in order to detect early kidney disease. ... the urinary albumin excretion rate, is an ...
... to near-patient urinalysis. The Chemstrip ... affordable, reliable alternative to visual ... fundamental, easy-to-use features, the Chemstrip ... office lab, clinic, and hospital ...
... UA is the first hand-held urine ... valuable lab bench space. Automation of ... in results between operators and transcription ... run, corrects for ambient temperature and ...
... first outside-the-balloon, dual-wire dilatation catheter. The ... innovative new approach to dilatation. Its unique, ... wires to create expansion planes at low ... ,The FX miniRAIL RX PTCA Catheter is ...
Medicine Products: